STOCK TITAN

Corvus Pharmaceu reported a $15.3M net loss for fiscal 2025. See the full CRVS financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.

Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference

Corvus Pharmaceuticals (CRVS) will participate in the 2026 Cantor Global Healthcare Conference in New York, NY, with leadership hosting one-on-one investor meetings and a fireside chat on September 10, 2026.

(Neutral)
(Neutral)
Tags

Corvus Pharmaceuticals (CRVS) will participate in the 2026 Cantor Global Healthcare Conference in New York, NY, with leadership hosting one-on-one investor meetings and a fireside chat on September 10, 2026.

The fireside chat is scheduled for 1:00 pm ET (10:00 am PT). A live webcast, available via the company’s investor relations website, will remain accessible for 90 days after the event.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

Market Context

CRVS closed at $14.20 on September 2, before this announcement. Against that baseline, the conferenc...
Analysis

CRVS closed at $14.20 on September 2, before this announcement. Against that baseline, the conference notice supplies scheduling information rather than operating results; the active S-3 shelf and high short positioning remain relevant context, with no new financing terms disclosed.

Key Figures

Presentation date: September 10, 2026 Presentation time: 1:00 pm ET Pacific time: 10:00 am PT +1 more
4 metrics
Presentation date September 10, 2026 2026 Cantor Global Healthcare Conference
Presentation time 1:00 pm ET Fireside chat
Pacific time 10:00 am PT Fireside chat
Webcast availability 90 days Following the event

Historical Context

5 past events · Latest: Aug 27 (Positive)
Pattern 5 events
Date Event Sentiment 24h Move Catalyst
Aug 27 Phase 1 clinical data Positive -0.1% Final Phase 1/1b data supported further soquelitinib development in T cell lymphoma.
Aug 06 2Q26 earnings report Negative +0.4% Quarterly net loss increased as clinical trial and personnel costs rose.
Jul 30 2Q26 earnings scheduling Neutral +0.5% Company scheduled its second-quarter financial results and business update.
Jun 09 Partner investment Positive +0.2% Corvus invested $5 million in Angel Pharmaceuticals' $13.5 million financing.
May 20 Healthcare conference presentation Neutral +7.3% Corvus announced presentations at Jefferies and Goldman Sachs healthcare conferences.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news reactions ranged from -0.07% to +7.3%, showing no consistent directional response.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the 2026 Cantor Global Healthcare Conference, which is being held in New York, NY. The fireside chat will be on Thursday, September 10, 2026 at 1:00 pm ET (10:00 am PT).

A webcast of the fireside chat will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of immune diseases and cancer. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is being evaluated in a registration Phase 3 clinical trial for relapsed/refractory PTCL and in a Phase 2 clinical trial for the treatment of atopic dermatitis. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn.

INVESTOR CONTACT:
Zack Kubow
Vice President, Investor Relations and Corporate Communications
Corvus Pharmaceuticals, Inc.
investors@corvuspharma.com

MEDIA CONTACT:
Julia Stern
Real Chemistry
media@corvuspharma.com


FAQ

When will Corvus Pharmaceuticals (CRVS) present at the 2026 Cantor Global Healthcare Conference?

Corvus Pharmaceuticals will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Thursday, September 10, 2026 at 1:00 pm ET (10:00 am PT) as part of its conference activities.

Where is the 2026 Cantor Global Healthcare Conference featuring Corvus Pharmaceuticals (CRVS) being held?

The 2026 Cantor Global Healthcare Conference, where Corvus Pharmaceuticals will host investor meetings and a fireside chat, is being held in New York, NY.

How can investors access the Corvus Pharmaceuticals (CRVS) fireside chat webcast from the 2026 Cantor conference?

The fireside chat webcast will be available live and on replay for 90 days. It may be accessed through the investor relations section of the Corvus Pharmaceuticals website.

Will the Corvus Pharmaceuticals (CRVS) fireside chat replay be available after the 2026 Cantor conference?

Yes. A webcast of the Corvus Pharmaceuticals fireside chat will be available live and for 90 days following the event via the investor relations section of the company’s website.